Health · 46 views
Twice-daily radiation linked to better quality of life in lung cancer trial
Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer…
Summary
Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population. At the same time, an exploratory analysis reported a longer median OS among patients who received twice-daily radiation, though the RT schedule was not randomized.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Bayer reaches Roundup settlement that could cost the company billionsContinue reading
- New structures come into view in brain wiring mapsContinue reading
- Cigarettes on silver platters at Bondi ‘clean’ beauty business lip gloss launch referred for investigationContinue reading
- Stress and anxiety are wearing workers down: How to spot your triggers and copeContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow